Cytodyn Inc (CYDY)

[HyGro]

Considering LL failed to meet ANY primary and secondary endpoints in the CD12 trial -- most medical professionals look at the complete trial data, not the cherry-picked data from NP. Selected "success stories" without the full trial context is misleading and unethical use of clinical trial data. Many patients on ECMO do survive. HCPs have been more successful at saving patients across the country without LL. Without having the large-scale trial data to assess drug efficacy versus a control is not evidence, but anecdote. That doesn't get a drug approved as you may have learned from LL's CoV clinical trial experience.